November is Lung Cancer Awareness Month. Lung cancer remains one of the most common and genomically diverse malignancies. Most of the 226,650 U.S. lung cancer cases expected in 2025 will be NSCLC. Advances in precision oncology are enabling therapies for EGFR, ROS1, KRAS G12D, and HER2 alterations.
November is also Pancreatic Cancer Awareness Month. Pancreatic cancer remains one of the most aggressive and challenging malignancies. In 2025, approximately 67,440 new cases are expected in the United States alone. Discoveries in BRCA‑related DNA repair defects and KRAS mutations are paving the way for new targeted and immunotherapy strategies.
At the Molecular Targets Meeting in Boston, Massachusetts, sessions highlighted the diverse applications of AACR Project GENIE data, including leveraging clinico-genomic information for research (Ken Kehl, DFCI), examining off-label targeted therapy utilization within GENIE BPC datasets (Jeremy Warner, Brown), and identifying novel drug targets through GENIE data analysis (Phillip Beer, Step Pharma).
